UNSPSC 51381505: Mesalamine or mesalazine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C7H7NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 4Q81I59GXC, chemically known as salicylic acid, 5-amino- but more generally known as mesalamine, which bears US NIH Compound Identifier 4075. European Medicines Agency schedules Mesalamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08782MIG.

The term MESALAZINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 39, No. 5, 1985, List 25). World Health Organization schedules mesalamine in its Anatomical Therapeutic Chemical (ATC) Classification. Mesalamine bears US NLM identifiers UMLS ID C0127615 and NCI Concept Code C29249. SMILES: OC1C(CC(N)CC1)C(=O)O.

UNSPSC 51381505 Mesalamine or mesalazine is a Commodity code that shows minimal alignment with recent state and local procurement activity. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, a direct-to-manufacturer pharmacy initiative, and generic multi-source pharmaceuticals and OTC products—none of which represent mesalamine procurement. The code appears underutilized or misapplied in current state and local solicitations, with no documented recent opportunities actually seeking mesalamine as the primary procurement object.

The mismatch between the code's nominal scope and recent posting activity suggests either sporadic demand for mesalamine specifically or systematic miscoding of pharmaceutical procurements under this Commodity. Issuing bodies engaged in pharmaceutical purchasing—Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance—are active in the market, but their recent competitive procurements target broader pharmaceutical classes or alternative products rather than mesalamine formulations. Business development professionals evaluating this code should monitor whether future state and local health departments, Medicaid agencies, or hospital systems issue dedicated mesalamine RFPs or ITBs, as the current posting volume does not support active pursuit.